140 related articles for article (PubMed ID: 21135171)
1. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
[TBL] [Abstract][Full Text] [Related]
2. Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.
Venier C; Guthmann MD; Fernández LE; Fainboim L
Clin Exp Immunol; 2007 Feb; 147(2):379-88. PubMed ID: 17223981
[TBL] [Abstract][Full Text] [Related]
3. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for antigen-specific cytotoxic T lymphocyte response stimulation under leukopenic conditions.
Oliver L; Fernández A; Raymond J; López-Requena A; Fernández LE; Mesa C
Vaccine; 2012 Apr; 30(19):2963-72. PubMed ID: 22391399
[TBL] [Abstract][Full Text] [Related]
4. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors.
Torréns I; Mendoza O; Batte A; Reyes O; Fernández LE; Mesa C; Guillén G
Vaccine; 2005 Dec; 23(50):5768-74. PubMed ID: 16112257
[TBL] [Abstract][Full Text] [Related]
6. Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens.
Mesa C; de León J; Fernández LE
Vaccine; 2006 Mar; 24(14):2692-9. PubMed ID: 16316710
[TBL] [Abstract][Full Text] [Related]
7. Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.
Gabri MR; Ripoll GV; Alonso DF; Gómez DE
J Cancer Res Clin Oncol; 2002 Dec; 128(12):669-77. PubMed ID: 12474053
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
[TBL] [Abstract][Full Text] [Related]
9. Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.
Aguilar FF; Barranco JJ; Fuentes EB; Aguilera LC; Sáez YL; Santana MD; Vázquez EP; Baker RB; Acosta OR; Pérez HG; Nieto GG
Vaccine; 2012 Oct; 30(46):6595-9. PubMed ID: 22921738
[TBL] [Abstract][Full Text] [Related]
10. Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells.
Fernández A; Oliver L; Alvarez R; Hernández A; Raymond J; Fernández LE; Mesa C
J Immunother Cancer; 2014; 2():5. PubMed ID: 24829762
[TBL] [Abstract][Full Text] [Related]
11. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.
Haile LA; Gamrekelashvili J; Manns MP; Korangy F; Greten TF
J Immunol; 2010 Jul; 185(1):203-10. PubMed ID: 20525890
[TBL] [Abstract][Full Text] [Related]
12. Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells.
Younos I; Donkor M; Hoke T; Dafferner A; Samson H; Westphal S; Talmadge J
Int Immunopharmacol; 2011 Jul; 11(7):816-26. PubMed ID: 21376153
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).
Estevez F; Carr A; Solorzano L; Valiente O; Mesa C; Barroso O; Sierra GV; Fernandez LE
Vaccine; 1999 Aug; 18(1-2):190-7. PubMed ID: 10501249
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
[TBL] [Abstract][Full Text] [Related]
16. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.
Labrada M; Clavell M; Bebelagua Y; León Jd; Alonso DF; Gabri MR; Veloso RC; Vérez V; Fernández LE
Expert Opin Biol Ther; 2010 Feb; 10(2):153-62. PubMed ID: 20088712
[TBL] [Abstract][Full Text] [Related]
17. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
18. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
19. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation.
Mesa C; De León J; Rigley K; Fernández LE
Vaccine; 2004 Aug; 22(23-24):3045-52. PubMed ID: 15297054
[TBL] [Abstract][Full Text] [Related]
20. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.
Aruga A; Aruga E; Chang AE
Cancer Res; 1997 Aug; 57(15):3230-7. PubMed ID: 9242454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
